Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news.

The Aussie biotech has chosen Cell Therapies as its preferred manufacturer for its cellular immunotherapies (living drugs to fight cancer) from its AdCella subsidiary.

Oldham says it’s an amazing opportunity that will enable Asian innovations to access western-regulated markets treating patients around the world for fibrotic diseases.

Tune in to hear AdAlta’s Tim Oldham on the partnership, its therapeutic assets, and more.